ClinicalTrials.gg
CompletedNCT00139711Updated Apr 1, 2008

Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer

A Phase 2 interventional study of Irinotecan and Docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Completed at 15 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-04-01.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing irinotecan in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 1 under way, none of them phase 3. Irinotecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 26
138 · median 41
Started
2003
with 4 others
Phase 2
18 of 28
1 open now
Registered
10th of 28
by date

Among the 28 studies testing irinotecan in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2003, is one of 18 in phase 2, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 28 studies testing irinotecan in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing irinotecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell lung cancer (NSCLC)

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven NSCLC
  • Recurrent or NCSLC

Exclusion criteria

Exclusion Criteria:

  • Prior ; except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer adequately treated an with non evidence of disease for at least 5 years
  • History or presence of brain or meningeal
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the activity and tolerability of the association of irinotecan and docetaxel according to three different schedules as second line treatment for recurrent or metastatic NSCLC.

Secondary outcomes

  1. Evaluate, in each arm, the time to progression, the duration of response and the survival

07

Study locations

15 sites
  • Pfizer Investigational Site
    Alzano Lombardo, BG 24022, Italy
  • Pfizer Investigational Site
    Gravedona, CO 22015, Italy
  • Pfizer Investigational Site
    Crema, CR 26013, Italy
  • Pfizer Investigational Site
    Gorgonzola, MI 20064, Italy
  • Pfizer Investigational Site
    Melegnano, MI 20070, Italy
  • Pfizer Investigational Site
    Vimercate, MI 20059, Italy
  • Pfizer Investigational Site
    Bari, 70126, Italy
  • Pfizer Investigational Site
    Benevento, 82100, Italy
  • Pfizer Investigational Site
    Borgomanero, 28021, Italy
  • Pfizer Investigational Site
    Brescia, 25123, Italy
  • Pfizer Investigational Site
    Mantova, 46100, Italy
  • Pfizer Investigational Site
    Milano, 20133, Italy
  • Pfizer Investigational Site
    Monza, 20052, Italy
  • Pfizer Investigational Site
    Napoli, 80136, Italy
  • Pfizer Investigational Site
    Varses, 21100, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Mar 2003
Completion
Jun 2006
Last update
Apr 1, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Apr 1, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00139711
Lead sponsor
Pfizer
First posted
Aug 31, 2005
Start date
Mar 2003
Completion
Jun 2006
Last update
Apr 1, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Docetaxel

Start the discussion